Drug Profile


Alternative Names: 11 1F4; CAEL 101; Ch mAb 11-1F4

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Caelum Biosciences
  • Developer Caelum Biosciences; Columbia University; National Cancer Institute (USA)
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Amyloid light-chain amyloidosis

Most Recent Events

  • 04 Jan 2017 CAEL 101 licensed to Caelum Biosciences worldwide for the treatment of Amyloid light chain amyloidosis
  • 04 Jan 2017 Interim efficacy and adverse events data from a phase I trial in Amyloid light chain amyloidosis presented at the 58th American Society of Hematology’s Annual Meeting (ASH-2016)
  • 04 Jan 2017 Caelum Biosciences plans to initiate a phase II trial in Amyloid light chain amyloidosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top